Carnosol suppresses cardiomyocyte hypertrophy via promoting the activation of AMPK pathway

Area of Science:

• Cardiovascular Research
• Pharmacology
• Molecular Biology

Background:

• Pathological cardiac hypertrophy is a significant risk factor for adverse cardiovascular events, including heart failure and sudden death.
• Current therapeutic strategies for myocardial hypertrophy are limited, highlighting the need for novel treatments.
• Identifying effective drugs for pathological cardiac hypertrophy is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the potential of carnosol as a therapeutic agent for pathological cardiac hypertrophy.
• To elucidate the underlying molecular mechanisms by which carnosol exerts its effects on the heart.
• To evaluate the efficacy of carnosol in preclinical models of cardiac hypertrophy.

Main Methods:

• In vitro experiments using PE-stimulated cardiomyocytes to assess carnosol's inhibitory effects.
• In vivo studies involving mice subjected to Transverse Aortic Constriction (TAC) surgery to induce cardiac hypertrophy and fibrosis.
• Western blot analysis to examine the phosphorylation activation of AMPK (AMP-activated protein kinase).

Main Results:

• Carnosol significantly inhibited PE-induced myocardial hypertrophy in vitro, with notable effects at 5 μM.
• Administration of 50 mg/kg carnosol protected mice against cardiac hypertrophy and fibrosis following TAC surgery.
• Carnosol's cardioprotective effects were mechanistically linked to the regulation of AMPK phosphorylation and activation.

Conclusions:

• Carnosol demonstrates significant potential as a therapeutic agent for pathological cardiac hypertrophy.
• The findings suggest that carnosol's mechanism of action involves the modulation of AMPK signaling pathways.
• Carnosol may represent a novel drug component for the treatment of myocardial hypertrophy and related cardiovascular diseases.